Bittium Oyj (HEL:BITTI)
Finland
· Delayed Price · Currency is EUR | Market Cap | 1.21B |
| Revenue (ttm) | 119.75M |
| Net Income (ttm) | 21.34M |
| Shares Out | 35.52M |
| EPS (ttm) | 0.60 |
| PE Ratio | 57.00 |
| Forward PE | 46.85 |
| Dividend | 0.15 (0.44%) |
| Ex-Dividend Date | Apr 23, 2026 |
| Volume | 93,844 |
| Average Volume | 87,896 |
| Open | 34.00 |
| Previous Close | 34.20 |
| Day's Range | 32.45 - 34.00 |
| 52-Week Range | 6.39 - 43.70 |
| Beta | 0.28 |
| RSI | 38.16 |
| Earnings Date | Mar 31, 2026 |
About Bittium Oyj
Bittium Oyj provides solutions for communications and connectivity, healthcare technology products and services, and biosignal measuring and monitoring in Finland, Germany, and the United States. It offers medical technologies products and solutions, including holter, long-term cardiac, and cardiac event monitoring; mobile cardiac telemetry; tools for biosignal analysis; medical service platform solutions; home sleep apnea testing; EEG monitoring for ICU and ER; and neuroscientific research, as well as Bittium Faros, HolterPlus, MedicalSuite, c... [Read more]
Financial Performance
In 2025, Bittium Oyj's revenue was 119.75 million, an increase of 40.34% compared to the previous year's 85.33 million. Earnings were 21.34 million, an increase of 193.66%.
Financial StatementsNews
Q4 2025 Bittium Oyj Earnings Call Transcript
Q4 2025 Bittium Oyj Earnings Call Transcript
Bittium Oyj Earnings Call Transcript: Q4 2025
Strong 2025 growth driven by defense segment, record order intake, and international expansion. 2026 guidance projects further sales and profit increases, with major licensing deals and new product development supporting long-term growth.
Original-Research: Bittium Oyj (von NuWays AG): BUY • news
Bittium Oyj Transcript: CMD 2025
The updated strategy emphasizes international growth, technological leadership, and operational scalability, with a focus on defense, engineering, and medical segments. Financial targets have been raised to 15–30% annual sales growth and 10–20% operating margin, supported by strong market drivers and selective M&A.
Bittium Oyj Earnings Call Transcript: Q2 2025
Net sales grew 11.3% year-on-year in the first half, driven by strong defense and security segment growth and a robust order book. Profitability was impacted by growth investments and a one-time medical segment restructuring, but the outlook remains positive with full-year guidance reaffirmed.
Bittium Oyj Earnings Call Transcript: Q4 2024
Net sales grew 13.2% year-on-year to EUR 85.2 million, with strong gains in Defense & Security and improved cash flow. 2025 guidance projects further growth, supported by a robust order book and ongoing strategic initiatives.
Bittium Oyj Earnings Call Transcript: Q2 2024
Net sales rose 6.5% year-over-year in H1 2024, with improved operating results and a strong order book. Defense and Security saw robust growth, while Medical and Engineering Services faced regulatory and market challenges. Full-year guidance remains positive.